Skip to main content
. 2009 Oct 22;115(2):187–197. doi: 10.1182/blood-2009-08-207126

Table 7.

Impact of molecular profiles in treatment outcome in prospective randomized trials

Trial (reference) CR OR PFS OS
CALGB 9712 (70) None significant None significant IgVH, del 11q, del 17p IgVH, del 11q, del 17p
ECOG 2997 (71) None significant None significant IgVH (for FC only), del 11q, del 17p Not stated
LRF CLL4 (59) del 11q, del 17p del 11q, del 17p IgVH, del 11q, del 17p Not stated

PFS indicates progression-free survival.